Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos
| Ano de defesa: | 2009 |
|---|---|
| Autor(a) principal: | |
| Orientador(a): | |
| Banca de defesa: | |
| Tipo de documento: | Tese |
| Tipo de acesso: | Acesso aberto |
| Idioma: | por |
| Instituição de defesa: |
Não Informado pela instituição
|
| Programa de Pós-Graduação: |
Não Informado pela instituição
|
| Departamento: |
Não Informado pela instituição
|
| País: |
Não Informado pela instituição
|
| Palavras-chave em Português: | |
| Link de acesso: | http://www.repositorio.ufc.br/handle/riufc/2731 |
Resumo: | A robust method for the determination of amoxicillin, norfloxacin, oxcarbazepine (OXC) and its active metabolite, 10,11-dihydro-10-hydroxycarbamazepine (MHD) in human plasma, using reversed-phase high-performance liquid chromatography (RP-HPLC) with ultraviolet, fluorescence and mass spectrometry detection, respectively, have been developed and valited. The methods involve precipitation of plasma protein with dichloromethane (amoxicillin), acetonitrile (amoxicillin and norfloxacin) and diethyl ether–diclhoromethane (60:40 v/v, oxcarbazepine), using cefadroxil, ciprofloxacin and deuterade carbamazepine (d10-carbamazepine) as internal standard (IS). Chromatographic separations were performed on a column Gemini C18 5 µm (150 X 4.6 mm), Synergi MAX-RP 4 µm (150 X 4.6 mm) and Luna C18 5 µm (150mm X 4.6 mm) with an elution system consisting of a mixture of 0.01 M buffer phosphate (pH 3.5)/acetonitrile (95:05 v/v), phosphate buffer–acetonitrile (85:15, v/v) and acetonitrile/water (50:50 v/v) + 20mM acetic acid, respectively. The calibration curve was linear, in the range of 0.5 to 40 µg/mL, 30 to 3500 ng/mL, 20 to 5250 ng/mL and 40 to 10,500 ng/mL. The recoveries at concentrations of 1.5, 15 and 30 µg/mL were foram 59.4%, 60.5% and 67.1% for amoxicillin; 90, 1400 and 2800 ng/mL were 103.5%, 100.2% and 100.2% for norfloxacin, 60, 2000 and 4000 ng/mL were 105.4, 89.2 and 92.8% for OXC and 120, 4000 and 8000 ng/mL were 88.4, 88.7 and 90.6% for MHD, respectively. The statistical evaluation of the developed method was conducted by examining within-batch and between-batch precision data, which were within the required limits. The methods were successfully applied in bioequivalence studies given 500 or 400-mg of the reference formulation / test amoxicillin and norfloxacin, and pharmacokinetic studies with formulation of oxcarbazepine suspension (6%) in healthy volunteers. |
| id |
UFC-7_680388b90cb31f371a181512e4fbc7d1 |
|---|---|
| oai_identifier_str |
oai:repositorio.ufc.br:riufc/2731 |
| network_acronym_str |
UFC-7 |
| network_name_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
| repository_id_str |
|
| spelling |
Martins, Ismael LeiteMaia, Maria Bernadete de SousaMoraes, Maria Elisabete Amaral de2012-06-12T14:04:46Z2012-06-12T14:04:46Z2009MARTINS, I. L. Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos. 2009. 195 f. Tese (Doutorado em Farmacologia) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2009.http://www.repositorio.ufc.br/handle/riufc/2731A robust method for the determination of amoxicillin, norfloxacin, oxcarbazepine (OXC) and its active metabolite, 10,11-dihydro-10-hydroxycarbamazepine (MHD) in human plasma, using reversed-phase high-performance liquid chromatography (RP-HPLC) with ultraviolet, fluorescence and mass spectrometry detection, respectively, have been developed and valited. The methods involve precipitation of plasma protein with dichloromethane (amoxicillin), acetonitrile (amoxicillin and norfloxacin) and diethyl ether–diclhoromethane (60:40 v/v, oxcarbazepine), using cefadroxil, ciprofloxacin and deuterade carbamazepine (d10-carbamazepine) as internal standard (IS). Chromatographic separations were performed on a column Gemini C18 5 µm (150 X 4.6 mm), Synergi MAX-RP 4 µm (150 X 4.6 mm) and Luna C18 5 µm (150mm X 4.6 mm) with an elution system consisting of a mixture of 0.01 M buffer phosphate (pH 3.5)/acetonitrile (95:05 v/v), phosphate buffer–acetonitrile (85:15, v/v) and acetonitrile/water (50:50 v/v) + 20mM acetic acid, respectively. The calibration curve was linear, in the range of 0.5 to 40 µg/mL, 30 to 3500 ng/mL, 20 to 5250 ng/mL and 40 to 10,500 ng/mL. The recoveries at concentrations of 1.5, 15 and 30 µg/mL were foram 59.4%, 60.5% and 67.1% for amoxicillin; 90, 1400 and 2800 ng/mL were 103.5%, 100.2% and 100.2% for norfloxacin, 60, 2000 and 4000 ng/mL were 105.4, 89.2 and 92.8% for OXC and 120, 4000 and 8000 ng/mL were 88.4, 88.7 and 90.6% for MHD, respectively. The statistical evaluation of the developed method was conducted by examining within-batch and between-batch precision data, which were within the required limits. The methods were successfully applied in bioequivalence studies given 500 or 400-mg of the reference formulation / test amoxicillin and norfloxacin, and pharmacokinetic studies with formulation of oxcarbazepine suspension (6%) in healthy volunteers.Foram desenvolvidos e validados três métodos robustos para a determinação de amoxicilina, norfloxacino, oxcarbazepina (OXC) e 10,11-dihidro-10-hidroxicarbamazepina (MHD) em plasma, utilizando cromatografia líquida de alta eficiência em fase reversa (RP-HPLC) com detecção ultravioleta, fluorescência e espectrometria de massa, respectivamente. Os métodos envolveram extração líquido-líquido, com diclorometano (amoxicilina), acetonitrila (amoxicilina e norfloxacino), éter etílico-diclorometano (60:40 v/v, oxcarbazepina), utilizando cefadroxil, ciprofloxacino e d10-carbamazepina como padrões interno (PI). Separações cromatográficas foram realizadas utilizando colunas Gemini C18 5 µm (150 X 4,6 mm), Synergi RP-MAX 4 µm (150 X 4,6 mm) e Luna C18 µm (150 X 4,6 mm), com sistemas de eluição constituídos por mistura de tampão fosfato de 0,01 M (pH 3,5)/acetonitrila (95:5 v/v), acetonitrila-tampão fosfato (85:15, v/v) e acetonitrila-água (50:50 v/v) + 20 mM ácido acético, respectivamente. As curvas de calibração foram lineares, nas faixas de 0,5 a 40 µg/mL, 30 a 3500 ng/mL, 20 a 5250 ng/ml e 40 a 10500 ng/ml. As recuperações nas concentrações de 1,5, 15 e 30 µg/ml foram de 59,4%, 60,5% e 67,1% para amoxicilina; 90, 1400 e 2800 ng/mL foram de 103,5%, 100,2% e 100,2% para norfloxacino, 60, 2000 e 4000 ng/ml foram de 105,4, 89,2 e 92,8% para OXC e 120, 4000 e 8000 ng/ml foram de 88,4, 88,7 e 90,6% para MHD, respectivamente. Os métodos validados incluíram avaliação de precisão e exatidão intra e interlote, assegurando que estes estavam dentro de limites admissíveis. Os métodos foram então aplicados com sucesso em estudos de bioequivalência, administrando 500 mg ou 400 mg das formulações referência/teste de amoxicilina e norfloxacino, e em estudos farmacocinéticos com formulação de oxcarbazepina suspensão (6%), em voluntários sadios.AmoxicilinaCromatografiaNorfloxacinoDesenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticosDevelopment and validation of bioanalytical methods for quantification of amoxicillin, norfloxacin and oxcarbazepine in pharmacokinetic studiesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisporreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFCinfo:eu-repo/semantics/openAccessLICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repositorio.ufc.br/bitstream/riufc/2731/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52ORIGINAL2009_tese_ilmartins.pdf2009_tese_ilmartins.pdfapplication/pdf3871788http://repositorio.ufc.br/bitstream/riufc/2731/1/2009_tese_ilmartins.pdf041d9a1fdf5ad9456c666dab99260b11MD51riufc/27312019-11-10 19:14:35.425oai:repositorio.ufc.br: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Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2019-11-10T22:14:35Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false |
| dc.title.pt_BR.fl_str_mv |
Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos |
| dc.title.en.pt_BR.fl_str_mv |
Development and validation of bioanalytical methods for quantification of amoxicillin, norfloxacin and oxcarbazepine in pharmacokinetic studies |
| title |
Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos |
| spellingShingle |
Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos Martins, Ismael Leite Amoxicilina Cromatografia Norfloxacino |
| title_short |
Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos |
| title_full |
Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos |
| title_fullStr |
Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos |
| title_full_unstemmed |
Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos |
| title_sort |
Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxicilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos |
| author |
Martins, Ismael Leite |
| author_facet |
Martins, Ismael Leite |
| author_role |
author |
| dc.contributor.co-advisor.none.fl_str_mv |
Maia, Maria Bernadete de Sousa |
| dc.contributor.author.fl_str_mv |
Martins, Ismael Leite |
| dc.contributor.advisor1.fl_str_mv |
Moraes, Maria Elisabete Amaral de |
| contributor_str_mv |
Moraes, Maria Elisabete Amaral de |
| dc.subject.por.fl_str_mv |
Amoxicilina Cromatografia Norfloxacino |
| topic |
Amoxicilina Cromatografia Norfloxacino |
| description |
A robust method for the determination of amoxicillin, norfloxacin, oxcarbazepine (OXC) and its active metabolite, 10,11-dihydro-10-hydroxycarbamazepine (MHD) in human plasma, using reversed-phase high-performance liquid chromatography (RP-HPLC) with ultraviolet, fluorescence and mass spectrometry detection, respectively, have been developed and valited. The methods involve precipitation of plasma protein with dichloromethane (amoxicillin), acetonitrile (amoxicillin and norfloxacin) and diethyl ether–diclhoromethane (60:40 v/v, oxcarbazepine), using cefadroxil, ciprofloxacin and deuterade carbamazepine (d10-carbamazepine) as internal standard (IS). Chromatographic separations were performed on a column Gemini C18 5 µm (150 X 4.6 mm), Synergi MAX-RP 4 µm (150 X 4.6 mm) and Luna C18 5 µm (150mm X 4.6 mm) with an elution system consisting of a mixture of 0.01 M buffer phosphate (pH 3.5)/acetonitrile (95:05 v/v), phosphate buffer–acetonitrile (85:15, v/v) and acetonitrile/water (50:50 v/v) + 20mM acetic acid, respectively. The calibration curve was linear, in the range of 0.5 to 40 µg/mL, 30 to 3500 ng/mL, 20 to 5250 ng/mL and 40 to 10,500 ng/mL. The recoveries at concentrations of 1.5, 15 and 30 µg/mL were foram 59.4%, 60.5% and 67.1% for amoxicillin; 90, 1400 and 2800 ng/mL were 103.5%, 100.2% and 100.2% for norfloxacin, 60, 2000 and 4000 ng/mL were 105.4, 89.2 and 92.8% for OXC and 120, 4000 and 8000 ng/mL were 88.4, 88.7 and 90.6% for MHD, respectively. The statistical evaluation of the developed method was conducted by examining within-batch and between-batch precision data, which were within the required limits. The methods were successfully applied in bioequivalence studies given 500 or 400-mg of the reference formulation / test amoxicillin and norfloxacin, and pharmacokinetic studies with formulation of oxcarbazepine suspension (6%) in healthy volunteers. |
| publishDate |
2009 |
| dc.date.issued.fl_str_mv |
2009 |
| dc.date.accessioned.fl_str_mv |
2012-06-12T14:04:46Z |
| dc.date.available.fl_str_mv |
2012-06-12T14:04:46Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
| format |
doctoralThesis |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
MARTINS, I. L. Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos. 2009. 195 f. Tese (Doutorado em Farmacologia) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2009. |
| dc.identifier.uri.fl_str_mv |
http://www.repositorio.ufc.br/handle/riufc/2731 |
| identifier_str_mv |
MARTINS, I. L. Desenvolvimento e validação de métodos bioanalíticos para quantificação da amoxilina, norfloxacino e oxcarbazepina em estudos farmacocinéticos. 2009. 195 f. Tese (Doutorado em Farmacologia) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2009. |
| url |
http://www.repositorio.ufc.br/handle/riufc/2731 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da Universidade Federal do Ceará (UFC) instname:Universidade Federal do Ceará (UFC) instacron:UFC |
| instname_str |
Universidade Federal do Ceará (UFC) |
| instacron_str |
UFC |
| institution |
UFC |
| reponame_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
| collection |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
| bitstream.url.fl_str_mv |
http://repositorio.ufc.br/bitstream/riufc/2731/2/license.txt http://repositorio.ufc.br/bitstream/riufc/2731/1/2009_tese_ilmartins.pdf |
| bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 041d9a1fdf5ad9456c666dab99260b11 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC) |
| repository.mail.fl_str_mv |
bu@ufc.br || repositorio@ufc.br |
| _version_ |
1847793166235729920 |